Cervical Polyp
Introduction
Cervical polyps are common, typically benign growths that originate from the surface of the cervix (ectocervix) or from the cervical canal (endocervix). These fleshy, finger-like projections are usually soft, red, or purple, and vary in size. While most cervical polyps are asymptomatic, some may cause symptoms such as vaginal bleeding, especially after intercourse, or unusual vaginal discharge. They are generally considered harmless and are not associated with an increased risk of cervical cancer.
Biological Basis
The exact cause of cervical polyps is not fully understood, but they are generally thought to arise from chronic inflammation, hormonal imbalances, or an abnormal response to estrogen. They are often composed of glandular tissue with a rich blood supply, covered by epithelial cells. Unlike cervical cancer, which is strongly linked to persistent human papillomavirus (HPV) infection, benign cervical polyps are not directly caused by HPV.
While the specific genetic underpinnings of benign cervical polyps are less extensively studied, research into related cervical conditions, such as cervical neoplasia and cancer, highlights a significant genetic component in overall cervical health. Studies have demonstrated a familial aggregation of cervical cancer, with estimates of common variant-based heritability ranging from 27% to 36%. [1] Genome-wide association studies (GWAS) have identified several genomic regions associated with susceptibility to cervical cancer and high-grade preinvasive lesions (CIN3). Key loci include the human leukocyte antigen (HLA) region on chromosome 6p21.32-33, which is consistently identified, as well as regions near CLPTM1L/TERT on 5p15.3, GSDMB on 17q12, PAX8 on 2q14, and 14q12. [1] For instance, the HLA-DQA1 lead SNP rs9272050 and CLPTM1L lead SNP rs27069 have been replicated in association with invasive cervical cancer, CIN3, and cervical dysplasia. [2] These genetic factors primarily influence immune responses to viral infections and cellular processes that, when dysregulated, can lead to neoplastic transformation, distinct from the mechanisms typically associated with benign polyps.
Clinical Relevance
Cervical polyps are usually detected during routine pelvic examinations. Although generally benign, their symptoms, such as abnormal vaginal bleeding, can mimic more serious conditions like cervical cancer or precancerous lesions. Therefore, it is clinically relevant to distinguish polyps from malignant growths. Most polyps are easily removed in an outpatient setting, and the tissue is typically sent for pathological examination to confirm its benign nature. Regular screening and prompt evaluation of any abnormal bleeding are crucial for early detection and management of all cervical conditions.
Social Importance
The presence of cervical polyps, while mostly benign, can cause anxiety and distress in women due to symptoms like unexpected bleeding and the need for medical evaluation and procedures. The importance of regular gynecological check-ups and cervical cancer screening (Pap tests) cannot be overstated, as these examinations are essential for detecting polyps, as well as precancerous changes and cervical cancer. Public health initiatives aimed at promoting screening and education about cervical health contribute to reducing the burden of cervical disease and improving women's reproductive health outcomes.
Methodological and Statistical Considerations
Previous genome-wide association studies (GWASs) investigating cervical disease have frequently encountered limitations due to modest sample sizes, particularly for invasive cervical cancer, leading to a predominant focus on precancerous conditions without distinct analyses for different cancer outcomes. [2] This constraint can diminish the statistical power required to robustly identify genetic associations and may skew findings towards common variants with larger effect sizes, potentially overlooking rarer genetic influences or those with more subtle effects. Furthermore, while imputation techniques have been employed to expand the range of genetic variants studied, their application has not always been comprehensive across all genomic regions, and some identified signals, such as in the CLPTM1L region, have shown sensitivity to whether variants were genotyped or imputed, raising questions about potential effect size inflation or false positives if not rigorously validated. [2] The challenge of replicating proposed risk variants, even with subsequent genotyping, underscores the need for larger, independent validation cohorts to confirm initial findings. [1]
The definition and classification of cervical phenotypes also present methodological challenges. Combining different grades of cervical dysplasia, such as CIN1-2 with CIN3, into a single "dysplasia" phenotype can dilute specific genetic signals relevant to the progression of higher-grade lesions or invasive cancer. [2] This broad phenotyping approach may obscure distinct genetic drivers for varying stages of cervical disease, thereby limiting the precision with which genetic risk factors can be identified and understood. Moreover, strict genome-wide significance thresholds, while necessary for multiple testing correction, might inadvertently lead to the omission of true genetic signals with smaller, yet clinically relevant, effect sizes.
Population Diversity and Phenotypic Heterogeneity
A significant limitation in current genetic studies of cervical disease is the underrepresentation of non-European populations, despite some studies attempting multi-ancestry meta-analyses. [3] Given the high prevalence of cervical malignancy in non-European populations, this lack of diversity restricts the generalizability of findings and impedes the accurate transferability and utility of genetic risk scores across different ancestral groups. The observed similarity in effect estimates across analyzed ancestries, while promising, cannot fully compensate for the limited sample sizes in non-European cohorts, necessitating broader inclusion of Black and Asian populations to enhance the global applicability of genetic insights. [3]
Furthermore, distinguishing the precise genetic underpinnings of various cervical phenotypes, including ectropion, cervicitis, dysplasia, and invasive cancer, remains complex. While some genetic associations may overlap between precancerous and cancerous conditions, the inability of non-HLA genetic risk scores to consistently achieve statistical significance for cervical cancer diagnoses after multiple testing correction, despite nominal significance, suggests that more refined phenotyping and larger, targeted studies are required. [3] The specialized imputation methods for the HLA region, relying on specific reference panels, also highlight the need for robust and diverse imputation resources to accurately capture genetic variation in this critical immune-related locus across different populations. [3]
Unaccounted Heritability and Gene-Environment Interactions
Current genome-wide association studies (GWASs) have only elucidated a fraction of the heritability observed for cervical cancer in family and registry studies, which report significantly higher heritability estimates (13–29%) compared to array-based estimates (around 7%). [3] This substantial "missing heritability" suggests that a considerable portion of genetic variation influencing cervical disease risk, including contributions from the HLA region, rare variants, or complex genetic architectures, remains to be fully characterized by current methodologies. [3] Bridging this gap requires further investigation into less common genetic variants and more comprehensive approaches to capture the full spectrum of genetic susceptibility.
The intricate interplay between genetic predisposition and established environmental risk factors, such as human papillomavirus (HPV) infection, smoking, and the number of sexual partners, is not yet fully understood or adequately explored. [2] While Mendelian randomization studies offer valuable insights into potential causal relationships, the complex confounding between environmental factors, where the effect of one (e.g., smoking) can be attenuated by accounting for another (e.g., number of sexual partners), underscores the need for more comprehensive gene-environment interaction analyses. [2] Moreover, a significant knowledge gap exists in translating identified genetic associations, particularly those in the non-coding genome, into functional biological mechanisms, posing challenges in fully understanding disease etiology and developing targeted interventions. [4]
Variants
Genetic variations play a crucial role in influencing an individual's susceptibility to various cervical conditions, including cervical polyps and more severe pathologies like cervical cancer and its precursors. These variants can affect immune responses, cellular regulation, and gene expression, thereby modulating the risk of abnormal cell growth in the cervical tissue.
Genetic variants within the Major Histocompatibility Complex (MHC) region on chromosome 6p21.3 are particularly significant in determining susceptibility to cervical pathologies. For example, rs2516448, located adjacent to the MICA gene, is strongly associated with cervical cancer risk. The risk allele of rs2516448 is in perfect linkage with a frameshift mutation (A5.1) in MICA, resulting in a truncated protein and lower levels of membrane-bound MICA, which is essential for activating anti-tumor immune responses. [5] Other key MHC variants, such as rs9272143 between HLA-DRB1 and HLA-DQA1, and rs3117027 at HLA-DPB2, are also independently associated with cervical cancer. [5] These variations can impact the body's immune system, affecting its ability to respond to infections like Human Papillomavirus (HPV), a known factor in cervical disease development.
Beyond the MHC, several other genetic loci contribute to the risk of cervical neoplasia and related conditions. The variant rs73730372, which serves as a strong proxy for rs115625939, exhibits a significant association with Cervical Intraepithelial Neoplasia Grade 3 (CIN3) risk and cervical cancer. [6] Another notable region is 14q12, where variants like rs225902 and rs225957 are implicated in cervical cancer susceptibility. Specifically, rs225902 shows an increasing odds ratio with the severity of cervical disease, from high-grade dysplasia to invasive cervical cancer, and demonstrates allele-specific repressive effects on promoter activity. [1] Such genetic variations can influence cell proliferation and differentiation in cervical tissues, potentially contributing to the formation of abnormal growths.
Further genetic variations impact critical cellular processes and gene expression, profoundly affecting cervical health. For instance, rs143668247 alters motifs in the POU5F1 gene, and its aberrant expression is linked to tumorigenesis. [7] The microRNA MIR365-2 has also been associated with cervical cancer, acting as both an oncogene and a tumor suppressor in different contexts, and targeting apoptotic markers such as BAX and BCL-2. [7] Additionally, variants like rs150806792 near INS-IGF2 and rs140991990 near SOX9 are reported to function as enhancer and promoter histone marks, suggesting a role in transcriptional regulation that could influence cervical cell growth and differentiation. [8] These genetic factors collectively modulate cellular pathways governing growth, programmed cell death, and gene regulation, all of which are fundamental to the development and progression of cervical pathologies.
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs146834132 | MEI4 - IRAK1BP1 | cervical polyp |
Classification, Definition, and Terminology
I am unable to provide a "Causes" section for 'cervical polyp' based solely on the provided context. The research material supplied focuses exclusively on "cervical preinvasive and invasive disease" (CIN3 and cervical cancer) and the genetic and environmental factors associated with these malignant or pre-malignant conditions. Cervical polyps are benign growths with a distinct etiology, and the information provided does not contain concrete, supportable evidence regarding their specific causes. As per the instructions, I cannot fabricate information, use external sources, or state that information is missing. Therefore, I must omit this section entirely.
Genetic Susceptibility and Regulatory Mechanisms
Studies indicate a significant genetic component influencing the susceptibility of cervical tissue to abnormal growth, with heritability estimates for cervical neoplasia ranging from 27% to 36%. [1] Genome-wide association studies (GWAS) have identified several genomic regions associated with cervical conditions, including loci on chromosomes 6p21.32-33 (the Human Leukocyte Antigen, HLA, locus), 5p15.3 (CLPTM1L/TERT), 17q12 (GSDMB), and 2q14 (PAX8). [1] These genetic variants, often found in the non-coding genome, suggest that regulatory functions play a crucial role in disease development. [1]
Genetic variations, such as single nucleotide polymorphisms (SNPs), can influence gene expression and function by altering regulatory elements like motifs, or by affecting adjacent genes. [1] For instance, heterozygosity in SMAD2 at rs4940086 has been linked to an increased risk of cervical cancer. [7] Furthermore, genes like CDH2 and CDH11, which encode cadherins, are known to regulate stem cell fate decisions, highlighting their potential importance in controlling cellular differentiation and proliferation within cervical tissues. [7] Aberrant expression of POU5F1 (POU Class 5 Homeobox 1) has also been associated with tumorigenesis. [7]
Cellular Signaling and Molecular Pathways
The regulation of cell growth, differentiation, and death in cervical cells involves complex molecular signaling pathways. The TGF-beta signaling pathway, for example, is critical for cellular homeostasis, and its termination is mediated by proteins like PPM1A, which functions as a Smad phosphatase. [7] Dysregulation in TGF-beta/Smad signaling, including altered expression and mutations, has been observed in human cervical cancers and HPV-induced lesions. [7] Another key enzyme, PPP3CA, encoding a catalytic subunit of calcineurin, is a calcium- and calmodulin-dependent serine-threonine protein phosphatase that plays vital roles in calcium-dependent signals and T-lymphocyte activation pathways. [7]
Cellular adaptor proteins also contribute significantly to these regulatory networks. NCK2, for instance, is an adaptor protein highly expressed in female genital and reproductive tissues, including the cervix, and is involved in regulating receptor protein tyrosine kinases. [7] Similarly, SKAP1 acts as a T-cell adaptor protein essential for coupling T-cell antigen receptor stimulation to the activation of integrins, thereby influencing immune cell function. [3] Furthermore, the GSDMB protein is involved in pyroptosis, a type of programmed cell death, and a specific splice variant (rs11078928) that deletes exon 6 can abolish this pyroptotic activity, potentially impacting the removal of abnormal cells. [3] The transmembrane protein CLPTM1L has been linked to promoting cell growth and altering cisplatin-mediated apoptosis in various tumors, suggesting its broader role in cellular proliferation and survival. [2]
Immune Response and Host-Pathogen Interactions
The host immune response is a critical determinant in the progression of cervical conditions, particularly in the context of human papillomavirus (HPV) infection. While most HPV infections are transient and cleared by an incompletely understood immune response, persistent infection can lead to cervical intraepithelial neoplasia (CIN) or invasive cervical cancer. [2] Host genetic factors, including specific HLA (Human Leukocyte Antigen) alleles, are major determinants of susceptibility, with both risk and protective alleles identified. [9] These immune-related proteins, along with their specific residue variants, provide further insight into the biological basis of cervical disease development. [9]
The effectiveness of the immune system in the cervix can be influenced by disruptions in key immune function pathways. Genes such as PAX8, CLPTM1L, and HLA are implicated in these pathways, affecting the immune system's ability to respond to cellular abnormalities. [2] The T-cell adaptor protein SKAP1 plays a critical role in T-cell activation and integrin coupling, which are essential for mounting an effective immune response. [3] Environmental factors like tobacco smoking and co-infections can also influence the immune response and increase the risk of disease progression. [1]
Epigenetic and Non-coding RNA Regulation
Beyond genetic sequence variations, epigenetic modifications and non-coding RNAs play significant roles in regulating gene expression and influencing cellular behavior in cervical tissues. Host epigenetic variation is a factor that can affect HPV clearance and the risk of progression to cervical cancer. [2] Long noncoding RNAs (lncRNAs), such as LINC00339, have been shown to promote cell proliferation and invasion in various cancers, including laryngeal squamous cell carcinoma and colorectal cancer, by interacting with microRNAs like miR-145 and miR-378a-3p. [3]
MicroRNAs (miRNAs) are another class of non-coding RNAs that critically regulate gene expression post-transcriptionally. MIR365-2, for instance, has been linked to both breast and cervical cancers, exhibiting either oncogenic or tumor suppressor effects depending on the cellular context. [7] This microRNA directly targets apoptotic markers BAX and BCL-2, which are crucial for programmed cell death, and is involved in the invasion and apoptosis processes in basal-like breast carcinoma by targeting Kruppel-like factor 12. [7] These regulatory networks highlight the intricate control over cellular functions, where dysregulation can contribute to abnormal cell growth and disease development in the cervix.
Cellular Signaling and Growth Control
The development and progression of cervical pathologies involve intricate cellular signaling networks that regulate cell growth, differentiation, and survival. The TGF-beta signaling pathway, for instance, is a critical regulator, with PPM1A functioning as a Smad phosphatase to terminate TGF-beta signaling, and dysregulation of TGF-beta/Smad signaling has been observed in human cervical cancers. [10] Genetic variations, such as heterozygosity at SMAD2 rs4940086, have been linked to an increased risk of cervical cancer. [11] Additionally, PAX8 signaling plays a dual role in cervical biology, being important for female genital system development while also potentially enhancing the proliferation of tumor cells. [3]
Other signaling components contribute to cervical cellular processes. NCK2, an adaptor protein highly expressed in female genital and reproductive tissues including the cervix, binds and recruits various proteins involved in the regulation of receptor protein tyrosine kinases. [12] Similarly, PPP3CA, encoding a catalytic subunit of calcineurin, is a calcium- and calmodulin-dependent serine-threonine protein phosphatase that plays critical roles in calcium-dependent signals and T-lymphocyte activation pathways. [12] These pathways, alongside broader MAP-kinase and hormone pathways, represent key regulatory axes whose dysregulation can contribute to abnormal cervical cell behavior and disease. [13]
Genetic and Epigenetic Regulatory Mechanisms
Cervical biology and pathology are profoundly influenced by genetic and epigenetic regulatory mechanisms that control gene expression. Genome-wide association studies (GWAS) have identified numerous genetic variants, many of which are located in the non-coding genome and possess regulatory functions, affecting enhancer, repressor, or promoter activities. [1] For example, specific single nucleotide polymorphisms (SNPs) can alter regulatory motifs or act as expression quantitative trait loci (eQTLs), linking genetic variation to changes in gene expression and disease risk. [3] Long-range epigenetic regulation, such as silencing, has been suggested to control the expression of genes like LOC654433 at the PAX8 locus, where decreased expression is associated with a protective effect against cervical cancer. [2]
Beyond DNA sequence variations, non-coding RNAs play significant roles in gene regulation. Long non-coding RNA LINC00339 has been prioritized as a candidate gene for cervical cancer signals and has been shown to promote cell proliferation, migration, and invasion in other cancer types. [3] MicroRNAs, such as miR-205 (targeting KLF12), miR-382 (a tumor suppressor), miR-141 (enhancing anoikis resistance), and miR-365 (promoting cell proliferation and invasion), exemplify post-transcriptional regulatory mechanisms that can be dysregulated in cancer. [14] Furthermore, epigenetic lesions like promoter hypermethylation of DNA repair genes are recognized as contributors to genetic lesions in human cancer. [15]
Immune Response and Cell Fate Modulation
The host immune response and mechanisms governing cell fate, particularly cell death, are integral to cervical health and disease. The human leukocyte antigen (HLA) locus, located on chromosome 6p21.32-33, is a consistently identified genomic region associated with cervical cancer, highlighting the role of immune recognition in disease susceptibility. [1] An immunosuppressive tumor microenvironment has also been observed in cervical cancer patients, impeding effective anti-tumor immunity. [16] PPP3CA (calcineurin) plays critical roles in T-lymphocyte activation pathways, further underscoring the immune component. [12]
Cell death pathways, such as pyroptosis, are also implicated. GSDMB is a candidate gene for cervical cancer, and its splice variant (rs11078928) deletes an exon that encodes amino acids critical for its pyroptotic activity, thereby abolishing this type of cell death. [3] This region associated with GSDMB has also been linked to various inflammatory and autoimmune conditions, suggesting broader implications for host responses. [3] CLPTM1L, a transmembrane protein, has been associated with cell growth promotion and altering cisplatin-mediated apoptosis, and may play a role in regulating viral transmission across epithelial barriers, particularly in HPV-driven cancers. [2]
Pathway Crosstalk in Cervical Pathogenesis
The progression of cervical pathologies arises from complex interactions and crosstalk between various molecular pathways, integrating genetic predisposition with cellular responses. The genetic associations identified for cervical dysplasia and cervical cancer are notably similar, suggesting that these conditions share underlying pathogenic mechanisms and that further studies could combine these phenotypes to increase power. [3] For example, PAX8 exhibits a dual role, being essential for female genital system development but also capable of enhancing the proliferation of tumor cells through overexpression. [3] Decreased PAX8 expression, potentially due to long-range epigenetic regulation, has been linked to a protective effect against uncontrolled cell growth and anti-apoptosis. [2]
Pathway dysregulation can manifest as altered cellular behaviors critical for disease progression. LINC00339 promotes cell proliferation, migration, and invasion. [17] Similarly, Cdc42 expression in cervical cancer is linked to tumor invasion and migration. [3] CDH2 and CDH11 (cadherins) are known regulators of stem cell fate decisions, hinting at their potential involvement in tissue homeostasis and aberrant growth in the cervix. [18] These interconnected pathways collectively contribute to the emergent properties of cervical pathology, from initial lesions to invasive disease.
Frequently Asked Questions About Cervical Polyp
These questions address the most important and specific aspects of cervical polyp based on current genetic research.
1. My mom had cervical polyps. Does that mean I'll get them too?
While benign cervical polyps themselves aren't strongly inherited, the broader risk for certain cervical conditions, including cervical cancer, can run in families. Studies show a significant heritability for cervical cancer, estimated between 27% and 36%. These genetic factors primarily influence your immune response to infections like HPV, which is crucial for overall cervical health.
2. I had a polyp removed. Will it come back because of my genes?
Benign polyps don't typically recur due to specific genetic predispositions, as their genetic basis is less understood. However, some individuals might have an underlying genetic susceptibility affecting their cellular responses or hormonal balance, which are thought to contribute to polyp formation. For more serious cervical conditions, your genes, like those in the HLA region, play a role in immune responses that affect recurrence risk.
3. Does my ethnic background affect my risk for polyps?
While specific genetic links for polyps and ethnicity are not well-defined, genetic studies on cervical cancer show that different ancestral groups may have varying genetic risk factors. Many studies have historically underrepresented non-European populations, meaning the full picture of genetic susceptibility across diverse backgrounds is still being clarified, particularly for genes influencing immune response to infections.
4. Can my daily stress or diet cause me to get a polyp?
Your daily habits like stress and diet can influence chronic inflammation and hormonal balance, which are thought to contribute to polyp formation. While the direct genetic link for benign polyps is less clear, maintaining a healthy lifestyle can support your overall cervical health. For more serious cervical conditions, genetic factors primarily influence your immune response to viral infections.
5. Is it true that HPV causes polyps, like it does cancer?
No, benign cervical polyps are not directly caused by HPV. This is a key difference from cervical cancer, which is strongly linked to persistent HPV infection. Genetic factors primarily influence your immune response to HPV and cellular processes that can lead to cancer, not benign polyp development.
6. If my sister had cervical cancer, am I more likely to get polyps or cancer?
You are generally not more likely to get benign polyps if your sister had cervical cancer, as polyps are distinct. However, you do have an increased likelihood for cervical cancer due to shared genetic predispositions. Studies show cervical cancer has a heritability of 27% to 36%, with specific genetic regions like HLA influencing immune responses to viral infections that can lead to cancer.
7. Why do I need a biopsy if my doctor thinks it's a polyp?
It's important because symptoms of benign polyps, like abnormal bleeding, can mimic more serious conditions like cervical cancer or precancerous lesions. While polyps are usually harmless, genetic factors play a significant role in susceptibility to cervical cancer. Pathological examination confirms the benign nature and rules out any genetically influenced cancerous changes.
8. Does getting older change my genetic risk for cervical problems?
While age itself doesn't change your inherited genes, the risk for cervical issues, including cancer, can accumulate over time as you're exposed to risk factors. Genetic factors influencing immune responses and cellular processes, such as those near CLPTM1L/TERT, become more relevant in how your body responds to these exposures as you age, potentially increasing susceptibility to serious conditions.
9. Can exercising regularly lower my genetic risk for cervical problems?
Exercising regularly can't change your inherited genetic makeup, but it can positively influence factors like inflammation and hormonal balance, which are thought to contribute to polyp formation. For cervical cancer, your genes affect how your body responds to viral infections, and a healthy lifestyle, including exercise, can support your overall immune system and resilience against disease.
10. Why do some people never get polyps or cervical issues?
Individual genetic differences play a significant role in susceptibility to cervical conditions. Some people inherit genetic variations, such as those in the HLA region, that give them a more robust immune response to infections like HPV. These genetic factors can reduce their risk for developing serious cervical conditions like cancer, even when exposed to various risk factors.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
[1] Ramachandran D, et al. "Genome-wide association study and functional follow-up identifies 14q12 as a candidate risk locus for cervical cancer." Hum Mol Genet, vol. 31, no. 14, 2022, pp. 2404-14.
[2] Bowden SJ, Mangino M, Langford C, et al. "Genetic variation in cervical preinvasive and invasive disease: a genome-wide association study." Lancet Oncol, 2021.
[3] Koel M, Võsa U, Lepamets M, et al. "GWAS meta-analyses clarify genetics of cervical phenotypes and inform risk stratification for cervical cancer." Hum Mol Genet, 2024.
[4] Edwards, S. L., et al. "Beyond GWASs: illuminating the dark road from association to function." American Journal of Human Genetics, vol. 93, 2013, pp. 779–797.
[5] Chen D, et al. "Genome-wide association study of susceptibility loci for cervical cancer." J Natl Cancer Inst, vol. 105, no. 10, 2013, pp. 730-37.
[6] Chen D, et al. "Pooled analysis of genome-wide association studies of cervical intraepithelial neoplasia 3 (CIN3) identifies a new susceptibility locus." Oncotarget, vol. 7, no. 25, 2016, pp. 38446-53.
[7] Adebamowo SN, Adebamowo CA, Famooto A, et al. "Genome-wide association study of prevalent and persistent cervical high-risk human papillomavirus (HPV) infection." BMC Med Genet, 2022.
[8] Masuda T, et al. "GWAS of five gynecologic diseases and cross-trait analysis in Japanese." Eur J Hum Genet, vol. 27, no. 11, 2019, pp. 1679-89.
[9] Leo, P. J. et al. "Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study." PLoS Genet, vol. 13, no. 8, 2017, e1006856.
[10] Adebamowo SN, et al. "PPM1A functions as a Smad phosphatase to terminate TGFbeta signaling." Cell, 2006.
[11] Haque PS, Apu MNH, Nahid NA, et al. "SMAD2 rs4940086 heterozygosity increases the risk of cervical cancer development among the women in Bangladesh." Mol Biol Rep, 2020.
[12] Adebamowo SN, Adebamowo CA, Famooto A, et al. "Genome, HLA and polygenic risk score analyses for prevalent and persistent cervical human papillomavirus (HPV) infections." Eur J Hum Genet, 2024.
[13] Azad AK, Bairati I, Qiu X, et al. "A genome-wide association study of non-HPV-related head and neck squamous cell carcinoma identifies prognostic genetic sequence variants in the MAP-kinase and hormone pathways." Cancer Epidemiol, 2016.
[14] Guan B, Li Q, Shen L, et al. "MicroRNA-205 directly targets Kruppel-like factor 12 and is involved in invasion and apoptosis in basal-like breast carcinoma." Int J Oncol, 2016.
[15] Esteller M. "Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes." Eur J Cancer, 2000.
[16] Piersma SJ. "Immunosuppressive tumor microenvironment in cervical cancer patients." Cancer Microenviron, 2011.
[17] Pan L, Meng Q, Li H, et al. "LINC00339 promotes cell proliferation, migration, and invasion of ovarian cancer cells via miR-148a-3p/ROCK1 axes." Biomed Pharmacother, 2019.
[18] Alimperti S, Andreadis ST. "CDH2 and CDH11 act as regulators of stem cell fate decisions." Stem Cell Res, 2015.